Literature DB >> 11256684

Serum lithium levels and the outcome of maintenance therapy of bipolar disorder.

H S Hopkins1, A J Gelenberg.   

Abstract

A literature review was conducted to locate studies that compared different serum lithium levels in the long-term treatment of patients with bipolar disorder and articles about factors that may affect serum lithium levels. Patients with bipolar disorder on long-term treatment with lithium are typically maintained at serum lithium concentrations between 0.6 and 1.0 mEq/L. Although there are individual exceptions, serum lithium levels below 0.6 mEq/L have been shown in controlled clinical trials to be less effective in preventing relapses than levels within this range, whereas levels much above 1.2 mEq/L can lead to toxicity. Differences in efficacy between levels within the accepted range have not been established. However, higher levels are associated with greater side effects, which can lead to poor compliance. Interindividual variation in pharmacokinetics and pharmacodynamics, as well as such external factors as diet and concomitant medications, can affect serum lithium levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11256684     DOI: 10.1034/j.1399-5618.2000.020304.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  9 in total

Review 1.  Lithium dosing and serum concentrations across the age spectrum: from early adulthood to the tenth decade of life.

Authors:  Soham Rej; Serge Beaulieu; Marilyn Segal; Nancy C P Low; Istvan Mucsi; Christina Holcroft; Kenneth Shulman; Karl J Looper
Journal:  Drugs Aging       Date:  2014-12       Impact factor: 3.923

Review 2.  Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations.

Authors:  Gin S Malhi; Michelle Tanious
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

3.  The effect of serum lithium levels on renal function in geriatric outpatients: a retrospective longitudinal study.

Authors:  Soham Rej; Karl Looper; Marilyn Segal
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

Review 4.  Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  Glycogen synthase kinase 3 beta regulates ethanol consumption and is a risk factor for alcohol dependence.

Authors:  Andrew van der Vaart; Xianfang Meng; M Scott Bowers; Angela M Batman; Fazil Aliev; Sean P Farris; Jennifer S Hill; Thomas A Green; Danielle Dick; Jennifer T Wolstenholme; Michael F Miles
Journal:  Neuropsychopharmacology       Date:  2018-09-06       Impact factor: 7.853

6.  Heart Attack in the Course of Lithium Overdose.

Authors:  Kalkan Asim; Yeniocak Selman; Yazici Suleyman; Karcioglu Ozgur; Bilir Ozlem; Ersunan Gokhan
Journal:  Iran Red Crescent Med J       Date:  2016-06-01       Impact factor: 0.611

7.  Preoperative Preparation of Hyperthyroidism for Thyroidectomy - Role of Supersaturated Iodine and Lithium Carbonate.

Authors:  Gopalakrishnan C Nair; Misha J C Babu; Riju Menon; Pradeep Jacob
Journal:  Indian J Endocrinol Metab       Date:  2018 May-Jun

8.  What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium.

Authors:  Willem A Nolen; Rasmus W Licht; Allan H Young; Gin S Malhi; Mauricio Tohen; Eduard Vieta; Ralph W Kupka; Carlos Zarate; René E Nielsen; Ross J Baldessarini; Emanuel Severus
Journal:  Bipolar Disord       Date:  2019-06-20       Impact factor: 6.744

9.  Potential Disease-Modifying Effects of Lithium Carbonate in Niemann-Pick Disease, Type C1.

Authors:  Shiqian Han; Huiwen Zhang; Mengni Yi; Xiaoqing Liu; Gustavo H B Maegawa; Yunding Zou; Qijun Wang; Dianqing Wu; Zhijia Ye
Journal:  Front Pharmacol       Date:  2021-06-09       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.